Genetic material secreted by bone marrow cells was used to reduce glioma tumor volume in a recent study.
The imaging technique of DTI allows neurosurgeons to visualize important pathways in the brain. This allows them to better adapt brain tumor surgeries and preserve language, visual function, and motor function while removing cancerous tissue.
Among patients undergoing surgery for a brain tumor, low T3 (triiodothyronine) syndrome has been found to be predictive of unfavorable clinical outcomes and depressive symptoms.
Low levels of the thyroid hormone triiodothyronine (T3) predict unfavorable outcomes after neurosurgery for the treatment of brain tumors.
Adipose tissue may provide a more efficient, less costly, and less invasive source of mesenchymal stem cells (MSCs) than bone marrow.
Combining the antiangiogenic bevacizumab with the kinase inhibitor dasatinib stopped glioblastoma metastasis after shrinking the tumors.
Fluorescence form 5-aminolevulinic acid (5-ALA) has been used to guide resection of recurrent GBM. Before surgery, the patient ingests 5-ALA, then the tumor cells fluoresce intraoperatively in response to certain wavelengths of light.
Large-scale genomic sequencing has revealed two DNA mutations that appear to drive about 15% of brain tumors known as meningiomas.
The forecast enables physicians to rapidly identify how well a tumor is responding to a particular therapy and allows a quick pivot to a new therapy in a critical time window if the current therapy is not effective.
ELTD1, a protein linked with angiogenesis, is the strongest candidate for a significant association with glioma out of nearly 200 possible markers.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|